Alzheimer's Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are 60 years of age or older.
- People who have been diagnosed with mild cognitive impairment (MCI) or early-stage Alzheimer's disease (possible or probable), confirmed using standard medical definitions.
- People whose cognitive test scores fall within a specific range, indicating at least mild memory or thinking difficulties (confirmed using a standard test called the MoCA).
- People who have at least some mild depressive symptoms, as measured by a standard mood rating scale called the MADRS.
- People who are either not taking antidepressants, cholinesterase inhibitors, or memantine, or who have been on a stable dose of these medications for at least 12 weeks.
- People who have chronic pain (nerve pain, body pain, or a mix of both) that has been present on most days for at least 3 months, with an average pain level of 4 or more out of 10.
- People whose level of daily functioning and memory difficulties fall within a specific range on a standard scale called the Clinical Dementia Rating (CDR).
- People who are able to understand and agree to participate in the trial on their own.
- People who have a caregiver, family member, or close person willing to take part as a study partner.
Who may not be able to join:
- People assessed by the trial medical team as having a significant risk of suicide.
- People whose overall physical or neurological health is considered too unstable to safely take part in a research study.
- People whose mental health is considered too unstable to safely take part in a talking therapy-based trial.
- People who need to be admitted to a psychiatric hospital for safety reasons at the time of joining.
- People who are not fluent in English.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Dimitris Kiosses, PhD, Weill Medical College of Cornell University
Phone: 914-997-4381
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in cognitive functioning, as measured by the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.